8-K: STAAR Surgical Reports 10% Sales Growth in Q3 2024, Driven by EVO ICL Adoption

STAAR Surgical announced a 10% increase in net sales to $88.6 million for the third quarter of 2024, fueled by growth in all regions and strong adoption of its EVO ICL lenses.

Summary

• STAAR Surgical reported a 10% increase in net sales, reaching $88.6 million in the third quarter of 2024, compared to $80.3 million in the same period last year.
• ICL sales also grew by 10% to $89.1 million, with a 6% increase in unit sales.
• The Americas region saw a 14% sales increase, EMEA grew by 12%, and APAC by 9%.
• Net income for the quarter was $10.0 million, or $0.20 per share, up from $4.8 million, or $0.10 per share, in the prior year.
• Adjusted EBITDA was $16.2 million, or $0.33 per share, compared to $16.5 million, or $0.33 per share, in the prior year.
• The company maintained its full-year 2024 net sales outlook of $340 million to $345 million and adjusted EBITDA of approximately $42 million, or $0.80 per diluted share.
• Gross profit margin was 77.3%, down from 79.2% in the prior year, due to reduced unit production.
• Operating expenses increased to $62.8 million from $57.3 million in the prior year, driven by higher general and administrative, and research and development costs.
• Cash, cash equivalents, and investments available for sale totaled $236.0 million as of September 27, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong sales growth and increased adoption of the company's products. While there are some challenges, such as a decrease in gross margin, the overall tone is optimistic and indicates a company performing well in its market.

Positives

• Double-digit sales growth was achieved despite a softening macroeconomic environment, particularly in China.
• The company is seeing increased adoption of EVO ICL for moderate myopia, expanding its total addressable market.
• The company's focus on customer engagement and market expansion is yielding solid results.
• The company has a strong cash position with $236.0 million in cash, cash equivalents, and investments.
• Net income per share doubled year-over-year.
• The company is maintaining its full-year outlook for net sales and adjusted EBITDA.

Negatives

• Gross profit margin decreased to 77.3% from 79.2% due to reduced unit production.
• Operating expenses increased due to higher general and administrative, and research and development costs.
• The macroeconomic environment softened in the second half of the quarter, particularly in China.
• Currency fluctuations, primarily the Japanese Yen, negatively impacted reported total net sales by $0.3 million.

Risks

• Global economic conditions could impact future sales and profitability.
• The company is dependent on demand from Asia, which is subject to economic and political risks.
• Regulatory approvals for new or improved products could be delayed or denied.
• The willingness of surgeons and patients to adopt new products and procedures is uncertain.
• International conflicts and trade disputes could negatively impact the business.

Future Outlook

The company maintained its full-year 2024 net sales outlook of $340 million to $345 million and adjusted EBITDA of approximately $42 million, or $0.80 per diluted share. The outlook includes EVO ICL sales growth of 17% in the Americas, 10% in EMEA, and 4% in APAC, including approximately 2% growth in China.

Management Comments

• Tom Frinzi, President and CEO, stated that the company achieved double-digit sales growth despite a softening macroeconomic environment.
• Mr. Frinzi also noted that the company is well-positioned to navigate current market dynamics, which they believe are transitory.
• Mr. Frinzi highlighted the increasing use of EVO ICL for moderate myopia, expanding the total addressable market.
• Mr. Frinzi emphasized the company's focus on customer engagement and market expansion.

Industry Context

The results indicate that STAAR Surgical is performing well in the refractive surgery market, particularly with its EVO ICL product line, despite a general softening in the market. The company is gaining market share and seeing increased adoption of its technology, even as laser vision correction procedures are declining.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the report notes that U.S. refractive procedures, predominantly laser vision correction, declined 18% in Q3 2024, while STAAR's U.S. ICL sales grew by 16%, indicating a significant outperformance.
• The company's global ICL sales growth of 10% and unit growth of 6% also suggest a strong performance compared to the overall market, which is experiencing a decline in refractive procedures.
• The company's focus on the EVO ICL product line and its expansion into moderate myopia treatment positions it well against competitors who may be more focused on laser vision correction.

Stakeholder Impact

• Shareholders will likely view the results positively due to the strong sales growth and increased profitability.
• Employees may be encouraged by the company's positive performance and growth prospects.
• Surgeons and patients will benefit from the continued development and adoption of the EVO ICL technology.
• Suppliers and creditors will likely see the company as a stable and reliable partner.

Next Steps

• The company will continue to monitor the impact of fiscal policy and stimulus in China on its near to midterm growth outlook.
• The company will continue to focus on customer engagement and market expansion.
• The company will continue to invest in customer education, innovative tools, and comprehensive practice support.
• The company will continue to advance its lower diopter strategies.

Key Dates

Keywords

EVO ICL, Implantable Collamer Lens, Ophthalmology, Refractive Surgery, Myopia, Astigmatism, Presbyopia, Net Sales, Adjusted EBITDA, Gross Margin, Financial Results, STAAR Surgical